FrancophonIA/ELRC3.0 huggingface dataset:
English: Observation (N = 167)
Slovenian: Opazovanje (n = 167)
English: The highest intravenous dose of rituximab tested in humans to date is 5000 mg (2250 mg/m2), tested in a dose escalation study in patients with CLL.
Slovenian: Največji do zdaj preizkušen intravenski odmerek rituksimaba pri človeku je 5.000 mg (2.250 mg/m2), preizkušen v študiji povečevanja odmerka pri bolnikih s kronično limfocitno levkemijo.
English: No incompatibilities between rituximab and polyvinyl chloride or polyethylene bags or infusion sets have been observed.
Slovenian: Med rituksimabom in vrečkami iz polivinilklorida ali polietilena ali infuzijskimi seti niso ugotovili inkompatibilnosti.
English: Some cases of late neutropenia occurring more than four weeks after the last infusion of rituximab were reported.
Slovenian: Poročali so o posameznih primerih pozne nevtropenije, ki se je pojavila več kot 4 tedne po zadnji infuziji rituksimaba.
English: In studies of rituximab in patients with Waldenstrom's macroglobulinaemia, transient increases in serum IgM levels have been observed following treatment initiation, which may be associated with hyperviscosity and related symptoms.
Slovenian: Pri bolnikih z Waldenstromovo makroglobulinemijo so v študijah z rituksimabom po začetku zdravljenja opazili prehodna zvišanja koncentracij IgM v serumu, kar pa je lahko povezano s hiperviskoznostjo in sorodnimi simptomi.
English: A total of 392/3095 (12.7%) patients with rheumatoid arthritis tested positive for ADA in clinical studies following therapy with rituximab.
Slovenian: Skupno je bilo 392 od 3.095 (12,7%) bolnikov z revmatoidnim artritisom v kliničnih študijah zdravljenja z rituksimabom pozitivnih na ADA.
English: • you have severe heart failure or severe uncontrolled heart disease and have granulomatosis with polyangiitis, microscopic polyangiitis or pemphigus vulgaris.
Slovenian: • imate hudo srčno popuščanje ali hudo, neurejeno srčno bolezen in imate tudi granulomatozo s poliangiitisom, mikroskopski poliangiitis ali navadni pemfigus.
English: This is because in a few cases, Ritemvia could cause hepatitis B to become active again, which can be fatal in very rare cases.
Slovenian: V maloštevilnih primerih namreč lahko bolezen zaradi zdravila Ritemvia ponovno izbruhne; to je lahko v zelo redkih primerih smrtno.
English: The primary objective for the study was complete remission (complete epithelialisation and absence of new and/or established lesions) at month 24 without the use of prednisone therapy for two months or more (CRoff for ≥ 2 months).
Slovenian: Primarni cilj študije je bila popolna remisija (CR - complete remission) (popolna epitelizacija in odsotnost novih in/ali razvitih lezij) po 24 mesecih brez uporabe prednizonskega zdravljenja v obdobju dveh mesecev ali več (CRoff za ≥ 2 meseca).
English: Ritemvia should be used in combination with CHOP chemotherapy.
Slovenian: Zdravilo Ritemvia je treba uporabljati v kombinaciji s kemoterapijo CHOP.
English: Neutropenia was not associated with an observed increase in serious infection in rituximab-treated patients.
Slovenian: Nevtropenija ni bila povezana z opaznim povečanjem resnih okužb med bolniki, ki so prejemali rituksimab.
English: Remission-induction therapy included IV prednisone, administered as per the investigator's discretion, preceded in some patients by methylprednisolone pulses, and pulse cyclophosphamide until remission was attained after 4 to 6 months.
Slovenian: Zdravljenje za indukcijo remisije je vključevalo intravenski prednizon, uporabljen po raziskovalčevi presoji, (nekateri bolniki so pred tem prejemali pulze metilprednizolona) in pulzni ciklofosfamid dokler ni bila dosežena remisija po 4 do 6 mesecih.
English: CHVP-IFN, R-CHVPIFN, 175
Slovenian: CHVP-IFN: 183 R-CHVP-IFN: 175
English: All patients received concomitant 60 mg oral prednisone on days 2-7 and 30 mg on days 8-14 following the first infusion.
Slovenian: Vsi bolniki so sočasno peroralno prejemali 60 mg prednizona od 2. do 7. dne in 30 mg od 8. do 14. dne po prvi infuziji.
English: Ritemvia is a biosimilar medicinal product.
Slovenian: Zdravilo Ritemvia je podobno biološko zdravilo.
English: 4.04 years
Slovenian: 4,04 let
English: 4 see also section infusion-related reactions below.
Slovenian: 4 Glejte tudi poglavje reakcije, povezane z infuzijo, spodaj.
English: ACR70 EULAR Response (Good/Moderate)
Slovenian: Odziv po EULAR (dober/zmeren)
English: The rate of serious cardiac events was 2.1 per 100 patient years (95% CI 3-15).
Slovenian: Delež resnih srčnih dogodkov je bil 2,1 na 100 bolnik-let (95-% interval zaupanja, 3-15).
English: Mean pre-therapeutic antibody titres against a panel of antigens (Streptococcus pneumoniae, influenza A, mumps, rubella, varicella) were maintained for at least 6 months after treatment with rituximab.
Slovenian: Povprečni predterapevtski titri protiteles proti naboru antigenov (Streptococcus pneumoniae, influenca A, mumps, rdečke, norice) so se ohranili najmanj 6 mesecev po zdravljenju z rituksimabom.
English: In patients with rheumatoid arthritis, 283 patients received subsequent therapy with a biologic DMARD following rituximab.
Slovenian: Pri bolnikih z revmatodnim artritisom jih je 283 po zdravljenju z rituksimabom prejelo nadaljnje zdravljenje z biološkim DMARD.
English: The benefit of rituximab maintenance treatment was confirmed in all subgroups analysed, regardless of induction regimen (CHOP or R-CHOP) or quality of response to induction treatment (CR or PR) (Table 9).
Slovenian: Korist vzdrževalnega zdravljenja z rituksimabom so potrdili v vseh analiziranih podskupinah, ne glede na indukcijsko shemo (CHOP ali R-CHOP) ali vrsto odgovora na indukcijsko zdravljenje (CR ali PR) (preglednica 9).
English: In general toxicity studies in cynomolgus monkeys no deleterious effects on reproductive organs in males or females were observed.
Slovenian: V študijah splošne toksičnosti pri opicah Cynomolgus niso opažali škodljivih učinkov na reproduktivne organe samcev ali samic.
English: In the post-marketing setting five cases of rituximab overdose have been reported.
Slovenian: Po prihodu zdravila na trg je bilo opisanih pet primerov prevelikega odmerjanja rituksimaba.
English: Severe infusion-related reactions with fatal outcome have been reported during post-marketing use of the rituximab intravenous formulation, with an onset ranging within 30 minutes to 2 hours after starting the first rituximab intravenous infusion.
Slovenian: Hude, z infuzijo povezane reakcije s smrtnim izidom, so bile opisane med obdobjem trženja z intravensko obliko rituksimaba; pojavile so se od 30 minut do 2 uri po začetku prve intravenske infuzije rituksimaba.
English: The overall safety profile was consistent with the well-established safety profile of rituximab in RA and GPA/MPA and no new adverse drug reactions were reported.
Slovenian: Na splošno so se varnostne značilnosti ujemale z dobro znanimi varnostnimi značilnostmi rituksimab pri RA in GPA/MPA; poročali niso o nobenih novih neželenih učinkih zdravila.
English: The primary outcome measure was achievement of complete remission at 6 months defined as a Birmingham Vasculitis Activity Score for Wegener's granulomatosis (BVAS/WG) of 0, and off glucocorticoid therapy.
Slovenian: Merilo primarnega opazovanega dogodka je bila dosežena popolna remisija po 6 mesecih, opredeljena kot ocena BVAS/WG (Birmingham Vasculitis Activity Score for Wegener's Granulomatosis) 0 in brez glukokortikoidnega zdravljenja.
English: In rheumatoid arthritis patients, immediate depletion of B cells in the peripheral blood was observed following two infusions of 1000 mg rituximab separated by a 14 day interval.
Slovenian: Pri bolnikih z revmatoidnim artritisom so takojšen upad števila celic B v periferni krvi opazili po dveh infuzijah 1.000 mg rituksimaba v presledku 14 dni.
English: • asthma, too little oxygen reaching the body organs
Slovenian: astma, telesne organe doseže premalo kisika, oteklost trebuha.
English: All patients were followed until month 28 (10 or 6 months, respectively, after the last rituximab infusion or azathioprine dose).
Slovenian: Vse bolnike so spremljali do 28. meseca (10 mesecev po zadnji infuziji rituksimab ali 6 mesecev po zadnjem odmerku azatioprina).
English: Serious cardiac reactions were reported at a rate of 1.3 per 100 patient years in the rituximab treated patients compared to 1.3 per 100 patient years in placebo treated patients.
Slovenian: Delež resnih neželenih učinkov, povezanih s srcem, je bil 1,3 na 100 bolnik-let pri bolnikih, ki so se zdravili z rituksimabom, v primerjavi z 1,3 na 100 bolnik-let pri bolnikih, ki so prejemali placebo.
English: M39021 CVP, 159 R-CVP, 162 53
Slovenian: CVP: 159 R-CVP: 162
English: Developmental toxicity studies have been performed in cynomolgus monkeys at doses up to 100 mg/kg (treatment on gestation days 20-50) and have revealed no evidence of toxicity to the foetus due to rituximab.
Slovenian: Študije razvojne toksičnosti so izvajali na opicah Cynomologus z odmerki do 100 mg/kg (zdravljenje od 20. do 50. gestacijskega dne) in niso pokazale znakov toksičnosti za plod zaradi rituksimaba.
English: The incidence of ADRs of any grade was similar in these two groups.
Slovenian: Incidenca neželenih učinkov katere koli stopnje je bila v obeh skupinah podobna.
English: All patients in the cyclophosphamide arm received azathioprine maintenance therapy during follow-up.
Slovenian: Vsi bolniki v skupini s ciklofosfamidom so med obdobjem spremljanja prejemali vzdrževalno zdravljenje z azatioprinom.
English: Clinical laboratory findings
Slovenian: Klinični laboratorijski rezultati
English: Minor relapses (not life threatening and not involving major organ damage) occurred in seven patients in the rituximab group (12%) and eight patients in the azathioprine group (14%).
Slovenian: Blažji recidivi (takšni, ki niso bili življenjsko ogrožajoči in niso vključevali okvare pomembnega organa) so se pojavili pri sedmih bolnikih v skupini z zdravilom rituksimab (12 %) in pri osmih bolnikih v skupini z azatioprinom (14 %).
English: • flushing or redness of the skin
Slovenian: • pordevanje ali rdečina kože,
English: The proportion of patients experiencing an infusionrelated reaction was 29% (11 patients), 40% (15 patients), 13% (5 patients), and 10% (4 patients) following the first, second, third, and fourth infusions, respectively.
Slovenian: Delež bolnikov, ki se jim je pojavila z infundiranjem povezana reakcija, je bil po prvem infundiranju 29% (11 bolnikov), po drugem 40% (15 bolnikov), po tretjem 13% (5 bolnikov) in po četrtem 10% (4 bolniki).
English: Treatment with Ritemvia uses four separate infusions given at weekly intervals.
Slovenian: Zdravljenje z zdravilom Ritemvia obsega štiri ločene infuzije, ki jih dobite v presledkih enega tedna.
English: Ask your pharmacist how to throw away medicines that you no longer use.
Slovenian: O načinu odstranjevanja zdravila, ki ga ne potrebujete več, se posvetujte s farmacevtom.
English: Very rarely, severe blistering skin conditions that can be life-threatening may occur.
Slovenian: Zelo redko se lahko pojavijo huda stanja z mehurji na koži, ki so lahko življenjsko ogrožujoča.
English: Parenteral medicinal products should be inspected visually for particulate matter and discolouration prior to administration.
Slovenian: Parenteralna zdravila je treba pred dajanjem vizualno podrobno pregledati glede prisotnosti delcev in obarvanja.
English: The proportions of rituximab treated patients showing a minimal clinically important difference (MCID) in HAQ-DI (defined as an individual total score decrease of >0.22) was also higher than among patients receiving methotrexate alone (Table 14).
Slovenian: Tudi delež z rituksimabom zdravljenih bolnikov, pri katerih se je pojavila minimalna klinično pomembna razlika (MCID, Minimal Clinically Important Difference) v HAQ-DI (opredeljena kot zmanjšanje individualne celotne ocene za > 0,22), je bil večji kot pri bolnikih, ki so prejemali samo metotreksat (preglednica 14).
English: 1 Frequency category derived from laboratory values collected as part of routine laboratory monitoring in clinical trials 2 Frequency category derived from post-marketing data.
Slovenian: 1Pogostnost pridobljena iz laboratorijskih vrednosti zbranih v okviru rutinskega laboratorijskega spremljanja v kliničnih preskušanjih.
English: Adverse reactions are listed in Table 2.
Slovenian: Neželeni učinki so navedeni v preglednici 2.
English: Patients with human anti-mouse antibody (HAMA) or anti-drug antibody (ADA) titres may have allergic or hypersensitivity reactions when treated with other diagnostic or therapeutic monoclonal antibodies.
Slovenian: Bolniki s prisotnimi humanimi protimišjimi protitelesi (HAMA) ali protitelesi proti zdravilu (ADA) imajo lahko alergijske ali preobčutljivostne reakcije, če jih zdravimo z drugimi diagnostičnimi ali terapevtskimi monoklonskimi protitelesi.
English: Sustained improvement in physical function as indicated by the HAQ-DI score and the proportion of patients achieving MCID for HAQ-DI were observed.
Slovenian: Ugotovljeno je bilo stalno izboljšanje funkcijske zmogljivosti, ki sta ga pokazala ocena HAQ-DI in delež bolnikov z doseženo MCID v HAQ-DI.
English: Safety and efficacy of Ritemvia have not been established in combination with other chemotherapies in diffuse large B cell non-Hodgkin's lymphoma.
Slovenian: Varnosti in učinkovitosti zdravila Ritemvia v kombinaciji z drugimi kemoterapijami pri difuznem velikoceličnem B ne-Hodgkinovem limfomu niso ugotavljali.
English: Each course of treatment is made up of two separate infusions which are given 2 weeks apart.
Slovenian: Vsak cikel zdravljenja obsega dve ločeni infuziji, ki ju boste dobili v presledku 2 tednov.
English: If you are not sure, talk to your doctor, pharmacist or nurse before you are given Ritemvia.
Slovenian: Če ste negotovi, se posvetujte z zdravnikom, farmacevtom ali medicinsko sestro, preden dobite zdravilo Ritemvia.
English: A total of 334 patients achieving a complete or partial remission following induction therapy were randomised in a second step to rituximab maintenance therapy (n=167) or observation (n=167).
Slovenian: Skupno je bilo 334 bolnikov, ki so po indukcijskem zdravljenju dosegli popolni ali delni odgovor, randomiziranih v drugi del zdravljenja, v katerem so prejemali vzdrževalno zdravljenje z rituksimabom (n=167), ali v opazovano skupino (n=167).
English: In the observation group, the median IgG level subsequently increased to above the LLN, but remained constant in the rituximab group.
Slovenian: V opazovani skupini se je mediana koncentracije IgG postopno povečevala nad spodnjo mejo normalne vrednosti, v skupini, ki je prejemala rituksimab pa je ostala nespremenjena.
English: V1 varied by body surface area (BSA) and CHOP therapy.
Slovenian: V1 se je razlikoval glede na telesno površino in zdravljenje s CHOP.
English: There was a higher incidence of grade 3/4 ADRs in patients with bulky disease than in patients without bulky disease (25.6% vs. 15.4%).
Slovenian: Bolniki z obsežno boleznijo so imeli višjo incidenco neželenih učinkov 3. ali 4. stopnje kot bolniki brez obsežne bolezni (25,6% v primerjavi s 15,4%).
English: Significant benefit from maintenance treatment with rituximab was also seen for the secondary endpoints event-free survival (EFS), time to next anti-lymphoma treatment (TNLT) time to next chemotherapy (TNCT) and overall response rate (ORR) in the primary analysis (Table 7).
Slovenian: Pomembna korist vzdrževalnega zdravljenja z rituksimabom se je pokazala tudi pri sekundarnih opazovanih dogodkih - preživetju brez dogodkov (event-free survival - EFS), času do naslednjega zdravljenja limfoma (time to next anti-lymphoma treatment - TNLT), času do naslednje kemoterapije (time to next chemotherapy - TNCT) in celokupnem odgovoru (overall response rate - ORR) v primarni analizi (preglednica 7).
English: Rituximab infusions were administered after an intravenous infusion of 100 mg methylprednisolone; patients also received treatment with oral prednisone for 15 days.
Slovenian: Infuzija rituksimaba je sledila intravenski infuziji 100 mg metilprednizolona; bolniki so 15 dni tudi peroralno jemali prednizon.
English: The median duration of response was 37.7 months in the R-CVP group and was 13.5 months in the CVP group (p < 0.0001, log-rank test).
Slovenian: Mediano trajanje odgovora je bilo 37,7 meseca v skupini z R-CVP in 13,5 meseca v skupini s CVP (p < 0,0001, log-rang test).
English: In addition, other serious viral infections either new, reactivated or exacerbated, some of which were fatal, have been reported with rituximab treatment.
Slovenian: Poleg tega so med zdravljenjem z rituksimabom opisane druge resne virusne okužbe, bodisi novonastale, ponovitve ali poslabšanja; nekatere so bile smrtne.
English: What Ritemvia looks like and contents of the pack
Slovenian: Izgled zdravila Ritemvia in vsebina pakiranja
English: 6 observed mainly in patients with prior cardiac condition and/or cardiotoxic chemotherapy and were mostly associated with infusion-related reactions
Slovenian: 6 Opaženi v glavnem pri bolnikih z obstoječimi boleznimi srca in/ali kardiotoksično kemoterapijo ter pretežno v zvezi z reakcijami, povezanimi z infuzijo.
English: Patients in the rituximab group who relapsed could receive an additional infusion of rituximab 1000 mg in combination with reintroduced or escalated prednisone dose.
Slovenian: Bolniki v skupini z rituksimab, ki se jim je pojavil recidiv, so lahko prejeli dodatno infuzijo 1.000 mg rituksimab v kombinaciji s ponovno uvedenim prednizonom ali povečanjem odmerka prednizona.
English: This is a disease of the lymph tissue (part of the immune system) that affects a type of white blood cell called B-Lymphocytes.
Slovenian: Ne-Hodgkinov limfom je bolezen limfatičnega tkiva (ta je del imunskega sistema), ki prizadene vrsto belih krvnih celic, limfocite B.
English: In clinical trials more than 3100 patients received at least one treatment course and were followed for periods ranging from 6 months to over 5 years; approximately 2400 patients received two or more courses of treatment with over 1000 having received 5 or more courses.
Slovenian: V kliničnih preskušanjih je več kot 3100 bolnikov prejelo najmanj en cikel zdravljenja, po tem so jih spremljali od 6 mesecev do več kot 5 let; približno 2.400 bolnikov je prejelo dva ali več ciklov zdravljenja, od teh pa več kot 1000 bolnikov 5 ali več ciklov zdravljenja.
English: • lower immunity - because of lower levels of anti-bodies called “immunoglobulins” (IgG)
Slovenian: zmanjšana imunost - zaradi manjše koncentracije protiteles, imenovanih imunoglobulini
English: Efficacy in autoantibody (RF and or anti-CCP) seropositive patients Patients seropositive to Rheumatoid Factor (RF) and/or anti-Cyclic Citrullinated Peptide (antiCCP) who were treated with rituximab in combination with methotrexate showed an enhanced response compared to patients negative to both.
Slovenian: Bolniki, serološko pozitivni za revmatoidni faktor (RF) in/ali anti-ciklični citrulinirani peptid (anti-CCP), ki so prejemali rituksimab v kombinaciji z metotreksatom, so imeli izrazitejši odziv kot bolniki, negativni za oba.
English: Based on the mechanism of action of rituximab and the knowledge that B cells play an important role in maintaining normal immune response, patients have an increased risk of infection following rituximab therapy (see section 5.1).
Slovenian: Glede na mehanizem delovanja zdravila rituksimab in dejstvo, da imajo celice B pomembno vlogo pri vzdrževanju normalnega imunskega odziva, imajo lahko bolniki, ki se zdravijo z zdravilom rituksimab, povečano tveganje za okužbe (glejte poglavje 5.1).
English: The incidence of ADRs of all grades and grade 3/4 ADR was similar in elderly patients compared to younger patients (< 65 years).
Slovenian: Incidenca neželenih učinkov vseh stopenj ter učinkov 3. ali 4. stopnje je bila pri starejših bolnikih podobna kot pri mlajših (< 65 let).
English: Table 6 Summary of key results from four phase III randomised studies evaluating the benefit of rituximab with different chemotherapy regimens in follicular lymphoma
Slovenian: Povzetek ključnih rezultatov štirih randomiziranih preskušanj III. faze, ki so ocenjevala korist rituksimaba v kombinaciji z različnimi shemami kemoterapije pri folikularnih limfomih
English: Patients should be closely monitored for the onset of cytokine release syndrome (see section 4.4).
Slovenian: Bolnike moramo zaradi možnosti pojava sindroma sproščanja citokinov (glejte poglavje 4.4) natančno opazovati.
English: When Ritemvia is given in combination with chemotherapy, standard dose reductions for the chemotherapeutic medicinal products should be applied.
Slovenian: Če zdravilo Ritemvia uporabimo v kombinaciji s kemoterapijo, je treba uporabiti standardno zmanjšanje odmerkov citostatikov.
English: However, dose-dependent pharmacologic depletion of B cells in the lymphoid organs of the foetuses was observed, which persisted post natally and was accompanied by a decrease in IgG level in the newborn animals affected.
Slovenian: Opazili pa so od odmerka odvisen farmakološki upad števila celic B v limfatičnih organih ploda, ki je trajal tudi postnatalno, spremljalo ga je tudi znižanje IgG pri pri prizadetih mladičih.
English: 4.06 years
Slovenian: 4,06 let
English: What Ritemvia is and what it is used for What Ritemvia is
Slovenian: Kaj je zdravilo Ritemvia in za kaj ga uporabljamo Kaj je zdravilo Ritemvia
English: The pharmacokinetic profile of rituximab when administered as 6 infusions of 375 mg/m2 in combination with 6 cycles of CHOP chemotherapy was similar to that seen with rituximab alone.
Slovenian: Farmakokinetični profil rituksimaba, dajanega v 6 infuzijah po 375 mg/m2 v kombinaciji s šestimi cikli kemoterapije CHOP, je bil podoben kot pri dajanju samega rituksimaba.
English: Medicines given before each Ritemvia administration
Slovenian: Zdravila, ki jih boste dobili pred vsakim dajanjem zdravila Ritemvia
English: The acute respiratory failure may be accompanied by events such as pulmonary interstitial infiltration or oedema, visible on a chest X-ray.
Slovenian: Akutno odpoved dihal lahko spremljajo spremembe, kot je infiltracija pljučnega intersticija ali pljučni edem, vidne na rentgenogramu prsnih organov.
English: Significant difference from placebo + MTX at the primary time point: ***p ≤ 0.0001
Slovenian: Značilna razlika v primerjavi s kombinacijo placebo + metotreksat ob času primarnega cilja preskušanja: ***p ≤ 0,0001
English: Symptoms of infusion-related reactions were similar in type and severity to those seen in RA and GPA/MPA patients.
Slovenian: Simptomi z infundiranjem povezanih reakcij so bili po vrsti in izrazitosti podobni simptomom, opaženim pri bolnikih z RA in GPA/MPA.
English: 1 includes reactivation and primary infections; frequency based on R-FC regimen in relapsed/refractory CLL 2 see also section infection below
Slovenian: 1 Vključuje reaktivacijo in primarne okužbe; pogostnost temelji na režimu R-FC pri bolnikih s KLL, pri katerih se je bolezen ponovila, ali pri neodzivnih bolnikih.
English: Medicinal products for the treatment of hypersensitivity reactions, e.g. epinephrine (adrenaline), antihistamines and glucocorticoids, should be available for immediate use in the event of an allergic reaction during administration of rituximab.
Slovenian: Zdravila za zdravljenje reakcij preobčutljivosti, npr. adrenalin, antihistaminiki in glukokortikoidi, morajo biti na voljo za takojšnjo uporabo, če bi se med dajanjem zdravila rituksimab pojavile alergijske reakcije.
English: Rituximab was administered on the first day of each treatment cycle.
Slovenian: Rituksimab je bil uporabljen prvi dan vsakega cikla zdravljenja.
English: Cases of grade 3 or 4 arrhythmia (including ventricular and supraventricular tachycardia) and angina pectoris during infusion were reported.
Slovenian: Med infuzijo sta se pojavili tudi aritmija 3. ali 4. stopnje (vključno z ventrikularno in supraventrikularno tahikardijo) in angina pektoris.
English: Units 2100, 2110, 2010, 2120, 2130 and 2500 Phase 18, Central Park Bridgend Industrial Estate Bridgend, CF31 3TY, UK
Slovenian: Units 2100, 2110, 2010, 2120, 2130 and 2500 Phase 18, Central Park